Wave Life Sciences Ltd.

NASDAQ:WVE

Biotechnology

Healthcare
$2.77 +1.63%

+$0.10 today

Market cap
$546.32M
Beta
-1.33
P/E (TTM)
-6.6
EPS (TTM)
-$0.92
52W Low $5.02High $21.73

Volume 2.21M

Average 4.86M

WVE Operating Income

Profit from core operations after operating expenses, before interest and taxes.

Wave Life Sciences Ltd.NASDAQ: WVE

Operating Income · Q1 FY2026 · quarter ended Mar 2026

Operating income remains negative

Q1 FY2026 operating income was -$31.3M, compared with -$49.8M a year earlier. Trailing-twelve-month operating income was -$196.88M.

Context

  • Operating income amounted to 504.1% of revenue in FY2025, up 402.2 pp from a year earlier.
  • Operating income grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether operating income reaches the consensus estimate from 15 analysts of -$173.72M (+19.3%) for the fiscal year ending Dec 2026, a step up from the -95.1% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$31.3M+44.6% QoQ
Last fiscal yearDec 2025
-$215.38M-95.1% YoY
LTMMar 2026
-$196.88M-56.6% YoY
Operating Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+37.2%-16.0%-53.2 pp
1 year-95.1%+19.3%+114.4 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Income history

USD · from the income statement

Latest · FY2025
(215.38M) USD
Year-over-year change
-95.1%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Income vs competitors

How WVE compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -56.6% is the 7th highest of 10, against a peer median of -39.8%.
  • Operating income amounts to 274.2% of revenue for WVE, versus a peer median of 196.7%.
WVE Competitors
Operating Income for WVE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALNYAlnylam Pharmaceuticals, Inc.LTM Jun 2026$999.78M USD+654.9%—20.8%
SRPTSarepta Therapeutics, Inc.LTM Mar 2026-$40.96M USD+65.1%—1.9%
PRQRProQR Therapeutics N.V.LTM Mar 2026-€46.45M EUR-39.8%—345.5%
BNTCBenitec Biopharma Inc.LTM Mar 2026-$53.94M USD-43.9%——
SLNSilence Therapeutics plcLTM Mar 2026-$86.59M USD——9396.6%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026-$89.22M USD-8.7%—196.7%
STOKStoke Therapeutics, Inc.LTM Mar 2026-$185.25M USD-584.4%—577.5%
WVEWave Life Sciences Ltd.LTM Mar 2026-$196.88M USD-56.6%—274.2%
NTLAIntellia Therapeutics, Inc.LTM Mar 2026-$420.72M USD+22.2%—636.6%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026-$565.42M USD-103.4%—58.9%
ARWRArrowhead Pharmaceuticals, Inc.LTM Sep 2026-$707.17M USD-819.1%—156.9%
Peer median (excluding WVE) —-39.8%—196.7%

Competitors are the stored peer set for WVE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue40.96M3.65M113.31M108.3M42.73M
Cost of Revenue00008.85M
Gross Profit40.96M3.65M113.31M108.3M33.88M
Gross Margin100.0%100.0%100.0%100.0%79.3%
Research & Development121.88M115.86M130.01M159.68M182.78M
Selling, General & Admin46.11M50.51M51.29M59.02M75.33M
Operating Expenses167.98M166.37M181.3M218.71M249.26M
Depreciation & Amortization9.84M10.11M9.21M8.66M8.85M
EBITDA(112.61M)(151.03M)(48.98M)(88.35M)(195.53M)
EBITDA Margin-274.9%-4138.9%-43.2%-81.6%-457.6%
Operating Income(127.02M)(162.72M)(68M)(110.4M)(215.38M)
Operating Margin-310.1%-4459.3%-60.0%-101.9%-504.1%
Interest Income30K00010.48M
Interest Expense00000
Other Income / Expenses4.57M1.58M9.81M13.4M11.01M
Income Before Tax(122.45M)(161.14M)(58.19M)(97.01M)(204.38M)
Pre-Tax Margin-298.9%-4416.1%-51.4%-89.6%-478.3%
Income Tax Expense(204K)681K(677K)00
Net Income(122.25M)(161.82M)(57.51M)(97.01M)(204.38M)
Net Margin-298.4%-4434.7%-50.8%-89.6%-478.3%
EPS (Basic)(2.36)(2.05)(0.54)(0.70)(1.21)
EPS (Diluted)(2.36)(2.05)(0.54)(0.70)(1.21)
Weighted Avg Shares51.83M78.86M106.1M138.28M168.65M
Weighted Avg Shares (Diluted)51.83M78.86M106.1M138.28M168.65M

Wave Life Sciences Ltd.

NASDAQ:WVE

Intrinsic Alpha fair value

Locked

Current Price

$2.77

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.